Name | No. | For Patients with | Purpose |
---|---|---|---|
HOVON 156 | 19-16 | Newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy |
This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy |
DSSG Group: Acute Leukaemia
HOVON 150
Name | No. | For Patients with | Purpose |
---|---|---|---|
HOVON 150 | 19-18 | Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |
This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |
BCNI GMI-1271-301
Name | No. | For Patients with | Purpose |
---|---|---|---|
BCNI GMI-1271-301 | 21-08 | Relapsed/Refractory Acute Myeloid Leukemia (AML) |
This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia |